A novel risk classification model integrating CEA, ctDNA, and pTN stage for stage 3 colon cancer: a post hoc analysis of the IDEA-France trial.

Thomas SamailleAntoine FalcozRomain CohenPierre Laurent-PuigThierry AndréGilles ManceauEdouard AuclinDewi Vernerey

Published in: The oncologist (2024)

Postoperative CEA value is a prognostic factor for DFS in stage 3 CC, independently of ctDNA and pTN. It advocates for systematic reporting in future adjuvant trials. Integrating both biomarkers with pTN could refine risk classification in stage 3 CC.

Keyphrases

prognostic factors
machine learning
deep learning
early stage
patients undergoing
study protocol
emergency department
adverse drug
circulating tumor
phase ii
electronic health record